The Kaplan-Meier analysis revealed that NPM1-mutated AML patients with high FTO expression were predicted shorter overall survival, while no prognostic value was shown in other m6A catalytic proteins (Figures 1D–F). Here, NPM1 is linked to acute myeloid leukemia.